Composition:
One coated tablet contains:.
active substance - benfotiamine 150 mg,
excipients - microcrystalline cellulose 122.0 mg, povidone K-30 8.0 mg, fatty acids glycerides 5.0 mg, colloidal silicon dioxide 7.0 mg, sodium carmellose 3.0 mg, talc 10.0 mg;
shell composition: shellac 3.0 mg, sucrose 70.875 mg, calcium carbonate 66.479 mg, talc 41.314 mg, acacia gum 10.155 mg, corn starch 7.340 mg, titanium
dioxide 10.932 mg, colloidal silicon dioxide 4.404 mg, povidone K-30 6.210 mg,
macrogol-6000 1.597 mg, glycerol 85% 2.262 mg, polysorbate 80 0.133 mg, wax
mountain glycolic 0.300 mg.
General description:
Vitamin.
Special conditions:
In older people, adverse reactions, except for the above, were noted.
It is not recommended to take a double dose of the drug if the previous dose was missed.
With Wernicke encephalopathy, the administration of dextrose should be preceded by taking thiamine.
Impact on the ability to drive vehicles and other mechanisms:
There is no data on the effect of the drug on the ability to drive vehicles and mechanisms used in therapeutic doses.
Drug Interactions:
Thiamine weakens the effect of depolarizing muscle relaxants (suxamethonium iodide, etc.), and is inhibited by fluorouracil.
Ethanol slows the absorption rate of thiamine after oral administration.
Pharmacodynamics:
Benfotiamine is a fat-soluble derivative of thiamine. Thiamine is converted into active thiamine pyrophosphate and, as a coenzyme, is incorporated into the pyruvate decarboxylase, alpha-ketoglutarate decarboxylase complexes, which are involved in the oxidative decarboxylation of pyruvic and alpha-ketoglutaric acids; transketolases - an enzyme of pentose phosphate shunt
Pharmokinetics:
Absorption is high throughout the small intestine. Before absorption, it is released from the bound state by digestive enzymes. After 15 minutes it is found in the blood, after 30 minutes - in other tissues. The concentration in the blood is relatively low, while free thiamine circulates in the plasma mainly in phosphate esters in red blood cells and white blood cells. Phosphorylation occurs in the liver. The most active phosphorus ester is thiamine diphosphate, which has coenzyme activity. It accumulates mainly in the liver, heart, brain, kidneys, spleen. 1/2 of the total amount is found in striated muscles and myocardium and about 40% in internal organs. It is excreted through the intestines and kidneys.
Indications:
Deficiency B1, confirmed by clinical and biochemical studies, developing against the backdrop of:
Inadequate and malnutrition (take-take);
-parenteral nutrition for a long time, hemodialysis;
chronic alcoholism (alcoholic cardiomyopathy, Wernicke encephalopathy, Korsakov syndrome);
- increased need for vitamin B1.
Polyneuropathy due to vitamin B1 deficiency. Typical signs of this deficiency are neurological disorders in the form of neuropathies with sensory disturbances (pain, tingling sensation, loss of sensation in the upper and lower extremities).
Contraindications:
Increased individual sensitivity to the components of the drug, sucrose / isomaltose deficiency, fructose intolerance glucose-galactose malabsorption, pregnancy, children's age.
Pregnancy and lactation
Pregnancy is a contraindication for the use of the drug.
Side effects:
Allergic reactions: angioedema, urticaria, skin itching.
Reported on isolated cases of disorders of the gastrointestinal tract: flatulence, diarrhea, constipation, nausea, abdominal pain.
The causal relationship with benfotiamine is currently not sufficiently supported, and is possibly dose-dependen
Ways of application:
For the treatment of vitamin B1 deficiency, 1 tablet is prescribed 1 time /, in rare cases, the dose can be increased.
With polyneuropathy, the initial dose is 1 tablet 2 for 3 weeks, then appoint 1 tablet daily.
Dragees are taken without chewing, washed down with a small amount of water.